Spectrophotometric assays
Objectives
Spectrophotometric assays allows the determination of the concentration of a substance of interest in various biological samples (urine, blood, plasma, tissue) and helps to better understand the mechanism of action of an active compound.
Summarized methodology
A wide range of assays have been validated based on direct colorimetric reactions or immuno-enzymatic detection (EIA / ELISA).
Pelvipharm is used to collect various sample types (urine, blood, plasma, tissue), while taking special care to adopt an appropriate storage of samples and to perform pre-analytical steps (extraction when needed) before any biochemical spectrophotometric assay.
Absorbance reading is performed using a Molecular Devices microplate reader (Spectramax 190) associated to SoftMax® Pro microplate analysis software.
Endpoints
A wide range of biochemical spectrophotometric assays have been validated at Pelvipharm, as follows :
 |
NB: Pelvipharm will gladly study the feasibility of performing additional spectrophotometric assays to meet its client’s needs.
J Sex Med (2010) : 7(1)p1:79-88
Oudot, A. et al.
Physiol Res (2009) : 58(4):499-509
Behr-Roussel, D. et al.
Eur Urol (2008) : 53(6):1272-1281
Behr-Roussel, D. et al.
Am J Hypertens (2008):21(11):1258-1263
Behr-Roussel, D. et al.
Am J Physiol – Regul (2005) : 288:R276-R283
Behr-Roussel, D. et al.
Atherosclerosis (2002) : 162:355-362
Links to applicable Targeted disorders / Pathophysiological models
- Atherosclerosis
- BPH (Benign Prostatic Hyperplasia)
- Diabetes
- ED (Erectile Dysfunction)
- Ejaculatory disorders (premature or delayed ejaculation / anejaculation)
- FSD (Female Sexual Dysfunction)
- Hypertension
- IC (Interstitial Cystitis) / Painful bladder syndrome
- Metabolic Syndrome and Obesity
- Myocardial Infarction
- NDO (Neurogenic Detrusor Overactivity)
- OAB (Overactive Bladder)
- SCI (Spinal Cord Injury)
Download this page in PDF